IFI16 in human prostate cancer

Molecular Cancer Research

Volumn 5, Issue 3, 2007, Pages 251-259

  Alimirah, Fatouma ^a   Chen, Jianming ^a   Davis, Francesca J ^a   Choubey, Divaker ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN RECEPTOR; GAMMA INTERFERON; INTERFERON; JANUS KINASE 1; PROTEIN C JUN; PROTEIN IFI 16; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; JANUS KINASE 1; MALE; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); UP-REGULATION;

EID: 34147160639     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0269     Document Type: Article

References (37)

1. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
2. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000;10: 125-44.
3. Kulaeva OI, Draghichi S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003;25:4118-27.
4. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A 2002;99:2830-5.
5. Xin H, Curry J, Johnstone RW, Nickoloff BJ, Choubey D. Role of IFI16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 2003;22:4831-40.
6. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioassays 1998;20:615-26.
7. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262:75-83.
8. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-8.
9. Shestakova E, Bandu MT, DolyJ, Bonnefoy E. Inhibition of histone deacetylation induces constitutive derepression of the β interferon promoter and confers antiviral activity. J Virol 2001;75:3444-52.
10. Nusinzon I, Horvath CM. Unexpected roles for deacetylation in interferon-and cytokine-induced transcription. J Interferon Cytokine Res 2005;25:745-8.
11. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
12. Rashid SF, Moore JS, Walker E, et al. Synergistic growth inhibition of prostate cancer cells by 1-α, 25 dihydroxyvitamin D(3) and its 19-norhexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001;20:1860-72.
13. Fronsdal K, Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005;62:299-306.
14. Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 2006;4:113-23.
15. Dunn GP, Sheehan KCF, Old LJ, Schreiber RD. IFN-unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 2005;65:3447-53.
16. Fujiuchi N, Aglipay JA, Ohtsuka T, et al. Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem 2004;279: 20339-44.
17. Alimirah F, Chen J, Xin H, Choubey D. Androgen receptor auto-regulates its expression by a negative feedback loop through up-regulation of IFI16 protein. FEBS Lett 2006;580:1659-64.
18. Xin H, Pereira-Smith OM, Choubey D. Role of IFI 16 in cellular senescence of human fibroblasts. Oncogene 2004;23:6209-17.
19. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett 2006;580:2294-00.
20. Won J, Chang S, Oh S, Kim TK. Small-molecule-based identification of dynamic assembly of E2F-pocket protein-histone deacetylase complex for telomerase regulation in human cells. Proc Natl Acad Sci U S A 2004;101: 11328-33.
21. Sen GC, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem 1992;267:5017-20.
22. Bhakat KK, Mitra S. Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J Biol Chem 2000;275:34197-204.
23. Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem Biophys Res Commun 2004;315:959-63.
24. Mukhopadhyay A, Bueso-ramos C, Chatterjee D, pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597-609.
25. Clarke CJ, Apostolidis V, Hii LL, Gough DJ, Trapani JA, Johnstone RW. Critical role of the transcription factor AP-1 for the constitutive and interferon-induced expression of IFI16. J Cell Biochem 2003;89:80-93.
26. Choubey D, Kotzin BL. Interferon-inducible p202 in the susceptibility to systemic lupus. Front Biosci 2002;7:e252-62.
27. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development. Curr Opin Cell Biol 1998;10:205-19.
28. Cano E, Hazzalin CA, Mahadevan LC. Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun. Mol Cell Biol 1994;14:7352-62.
29. Johnstone RW, Trapani JA. Transcription and growth regulatory functions of the HIN-200-family of proteins. Mol Cell Biol 1999;19:5833-8.
30. Johnstone RW, Wei W, Greenway A, Trapani JA. Functional interaction between p53 and the interferon-inducible nucleoprotein IFI16. Oncogene 2000; 19:6033-42.
31. Aglipay JA, Lee SW, Okada S, et al. A member of the pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway. Oncogene 2003;22:8931-8.
32. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4:1311-9.
33. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
34. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005;5:8-18.
35. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994;371:346-7.
36. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001;287:705-13.
37. Geng Y, D'Souza S, Xin H, Walter S, Choubey D. p202 levels are negatively regulated by serum growth factors. Cell Growth Differ 2000;11:475-83.